BioMarin : Children Treated With Vosoritide Show Cumulative Height Gain At Year 2

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. (RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) said that children in the open-label long-term extension of the phase 3 study of vosoritide maintained an increase in annual growth velocity through the second year of continuous treatment. It is an investigational, once daily injection analog of C-type Natriuretic Peptide. The company noted that... To keep reading about BioMarin : Children Treated With Vosoritide Show Cumulative Height Gain At Year 2, Click on the link. Seoul, Korea
http://dlvr.it/Rp4dxR

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

AT&T Sells DirecTV Stake To Private Equity Firm TPG

7 lies to stop telling yourself if you want to become mentally stronger